Citius Oncology, Inc. (CTOR)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
CTOR
Citius Oncology, Inc.
$0.78
-2.00%
HEALTHCARE · Cap: $72.48M
TAK
Takeda Pharmaceutical Co Ltd ADR
$15.60
+0.97%
HEALTHCARE · Cap: $49.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 80295727% more annual revenue ($4.51T vs $5.61M). TAK leads profitability with a 4.3% profit margin vs 0.0%. TAK earns a higher WallStSmart Score of 57/100 (C).
CTOR
Avoid21
out of 100
Grade: F
TAK
Buy57
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 330.2% YoY
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
3.9% revenue growth
ROE of 2.5% — below average capital efficiency
4.3% margin — thin
Operating margin of 3.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : CTOR
The strongest argument for CTOR centers on Debt/Equity, Price/Book.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.40 suggests the stock is reasonably priced for its growth.
Bear Case : CTOR
The primary concerns for CTOR are Revenue Growth, EPS Growth, Market Cap.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 42.5x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
CTOR carries more volatility with a beta of 3.57 — expect wider price swings.
TAK is growing revenue faster at 3.9% — sustainability is the question.
CTOR generates stronger free cash flow (-4M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TAK scores higher overall (57/100 vs 21/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Citius Oncology, Inc.
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Citius Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies tailored for underserved patient populations. With a robust pipeline of proprietary technologies, Citius aims to enhance treatment efficacy and safety across various cancer indications. The company is strategically advancing its promising drug candidates through pivotal clinical trials and regulatory processes, leveraging partnerships and rigorous clinical research standards to optimize patient outcomes and address critical needs in the oncology sector.
Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?